Indications
The 1% ophthalmic preparation of Atropine Sulfate is used as a cycloplegic or mydriatic for refraction, and also when the iris or uveal tract needs to be dilated during acute inflammatory conditions. The 0.01% ophthalmic preparation is used to slow the progression of myopia in children aged 4 to 14 years. Mydri Atropine Sulfate treatment may be started in children when their myopia progresses.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Atropine Sulfate works by suppressing the progression of myopia, though the exact way it does this is not fully settled. Muscarinic receptors are found widely in the tissues of the eye, and they are known to have a part in eye growth and development as well as in accommodation. Preclinical studies suggest that Atropine Sulfate binds to muscarinic receptors on scleral fibroblasts and possibly in the retina, mainly the M1, M3 and M4 subtypes. This changes the activity of cell signaling proteins and enzymes such as MEK-ERK-MAPK and transglutaminases, and possibly dopamine release. The result is remodeling or strengthening of the sclera, which leads to a reduction in axial length and vitreous chamber depth, and so to a suppression of myopia progression.
Pregnancy & Breastfeeding
Atropine Sulphate can be absorbed into the body after it is put in the eye. Even so, no significant effects on the fetus have been reported. Once absorbed, a very small amount of it passes into breast milk. In nursing infants of mothers using Atropine eye preparations, it may cause side effects such as rapid pulse, fever or dry skin.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.